New patents protect SigNature T molecular tagging technology and a multimode reader device enabling IT integrated instant authentication
STONY BROOK, N.Y. (November 3, 2017) – Applied DNA Sciences, Inc. (“Applied DNA,” “the Company,” NASDAQ: APDN) is pleased to announce the issuance of U.S. Patent No. 9,790,538 (US 2014/0256881) entitled “Alkaline Activation for Immobilization of DNA Taggants” and a Notice of Allowance of U.S. Patent Application 15/027,454 (US 2016/0246892) entitled “Multimode Image and Spectral Reader.”
The ‘538 patent, issued on October 17, 2017, protects the core technology powering Applied DNA’s SigNature T molecular tags in the textile industry and is directed at methods of enhancing the binding affinity of molecular tags to a variety of textile substrates, including cotton, wool, cellulosic materials and man-made fibers. The enhanced binding affinity of the SigNature T molecular tags enables them to survive extremely harsh manufacturing processes, such as those found in leather, cotton and synthetics manufacturing. The patented methods are currently used in wide range of SigNature T applications, and are integral to the Company’s pursuit of a global textile industry anticipated to grow to $910 billion in sales in 2019 from $750 billion in 2015*.
The ‘454 Application, allowed on October 26, 2017 will issue as a patent, and protects Applied DNA’s proprietary Multimode Image and Spectral Reader (“MMR”) device that provides for instant detection and identification of a wide variety of optical, molecular, olfactory and radio based taggants through the use of electronic sensor capture and digital database analysis. The handheld MMR device can rapidly detect one or more taggants and compare the detected taggants to library of known taggant configurations to provide instant authentication.
“We take great pride in the patenting of our SigNature T molecular tags, providing us with broad long-term market exclusivity. In addition, the patenting of our MMR device paves the way for the instant authentication of a broad range of taggants and exciting licensing opportunities,” said Dr. James Hayward, president and CEO of Applied DNA. “Protecting our innovations has always been a cornerstone of Applied DNA. Our robust intellectual property portfolio is more important than ever, as industry awareness and acceptance of our technologies is rapidly growing.”
The issuance of the ‘538 patent raises Applied DNA’s patent portfolio to 53, in addition to over 70 pending applications.
*Work Textile Information Network’s ‘World Textile Outlook 2016’ (click for free report).
To learn more about Applied DNA visit www.adnas.com.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.
We make life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-based “CertainT®” platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products.
SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature®T and fiberTyping®, targeted towards textiles and apparel, BackTrac™ and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track-and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.
The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 6, 2016, and our subsequent quarterly reports on Form 10-Q filed on February 9, 2017, May 11, 2017 and August 10, 2017 which are available at www.sec.gov. APDN , undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.
investor contact: Sanjay Hurry, 212-838-3777, email@example.com
media contact: Angie Mathews, 781-639-4924, firstname.lastname@example.org
program contact: MeiLin Wan, 631-240-8849, email@example.com
web: www.adnas.com, twitter: @APDN